Natural Ropivacaine hydrochloride hcl Powder supplier

CAS: 98717-15-8

MF: C17H27ClN2O

MW: 310.86

EINECS: 1312995-182-4

Specification​: 99% min Ropivacaine hydrochloride Powder

Sample: Ropivacaine hydrochloride Powder Avaliable

Packaging: 1kg/bag, 25kg/drum

Brand: Ausreson

MOQ: 1 kg

Appearance: white powder

Storage: Cool Dry Place

Shelf Life: 2 Years

Test Method: HPLC

Last updated: March 2026

Ropivacaine hydrochloride Powder Usage and Synthesis.

RopivacaineHCl is a local anesthetic. RopivacaineHCl causes nerve block by reversibly inhibiting sodium ion flow in nerve fibers. The pKa of RopivacaineHCl is ~8.2. RopivacaineHCl has the potential to induce cardiovascular toxicity and CNS toxicity at high plasma concentrations.

How Ropivacaine Enhances Safety

• Selective Sodium Channel Blockade: Ropivacaine inhibits the influx of sodium ions through the nerve fiber membranes. In 2026, it is specifically prized for its differential block, where it selectively targets smaller pain fibers ($A\delta$ and $C$ fibers) more effectively than larger motor fibers.

• Reduced Cardiotoxicity Profile: Being a pure $S(-)$-enantiomer, Ropivacaine has a lower affinity for cardiac sodium channels than racemic mixtures like Bupivacaine. This significantly reduces the risk of arrhythmias and cardiac arrest during accidental intravascular injection.

• Vasoconstrictive Properties: Unlike most local anesthetics that cause vasodilation, Ropivacaine has inherent mild vasoconstrictive effects at clinical concentrations, which slows its own absorption and prolongs the duration of action.

• Rapid Clearance: 2026 pharmacokinetics data show that Ropivacaine is rapidly metabolized by the liver (CYP1A2), reducing the cumulative risk during long-term epidural infusions.

Uses of Ropivacaine hydrochloride.

Ropivacaine is a new type of long-acting amide local anesthetic, which has a long duration of action and has anesthetic and analgesic effects.

Why "99% Pure Crystalline API" is the 2026 Quality Standard

1. Crystalline Hydrate Stability: In 2026, the Monohydrate form of Ropivacaine HCl is the standard for powder stability. This ensures the API remains stable under varying humidity levels during the manufacturing of injectable solutions.

2. Ultra-High Enantiomeric Purity (≥ 99.5%): The safety of Ropivacaine depends on the absence of the $R(+)$-isomer. 2026 standards require Chiral HPLC verification to ensure near-absolute $S$-isomer purity.

3. Endotoxin-Free Manufacturing: For spinal and epidural applications, the powder must be certified Apyrogenic. 2026's gold-standard powders undergo rigorous depyrogenation processes to meet strict "Sterile-Grade" requirements (<0.5\ EU/mg).

Pharmacological action of Ropivacaine hydrochloride.

Ropivacaine, the first pure levo-body long-acting amide local anesthetic, has both anesthetic and analgesic effects, with large doses producing surgical anesthesia and small doses producing sensory block (analgesia) accompanied only by limited non-progressive motor nerve block. Addition of epinephrine did not change the blocking intensity and duration of ropivacaine. Ropivacaine reversibly blocks impulse conduction along nerve fibers by blocking the flow of sodium ions into the membrane of nerve fibers. Local anesthetics may also have a similar effect on excitable cell membranes such as brain cells and cardiomyocytes, and if excess drugs enter the systemic circulation quickly, the central nervous system and cardiovascular system will show signs and symptoms of intoxication. Pregnant ewes did not show a greater sensitivity to ropivacaine than non-pregnant ewes.

Intravenous administration of ropivacaine was well tolerated in healthy volunteers, and clinical experience with this drug suggests a good safety range. Indirect cardiovascular effects (hypotension, bradycardia) may occur with epidural use, depending on the degree of parasympathetic block. At high concentrations, the inhibitory effect of bupivacaine on the composite action potential of Class A and Class C nerve fibers was 16% and 3% stronger than that of Ropivacaine hydrochloride, respectively, indicating that the sensory blocking effect of Ropivacaine hydrochloride and bupivacaine hydrochloride was similar, but the motor blocking effect of Ropivacaine hydrochloride was weak. At low concentration, ropivacaine hydrochloride mainly blocks sensory nerve fibers and has a light block on motor nerve fibers, that is, Ropivacaine hydrochloride has a high degree of separation of sensory and motor nerve blocks, and has a unique advantage for postoperative epidural analgesia.

Frequently Asked Questions (FAQ)

In 2026, the consensus is clear: Ropivacaine provides a wider safety margin (higher threshold for CNS and cardiac toxicity) and more consistent motor sparing, making it superior for "walking epidurals" in labor.

Ropivacaine is a long-acting anesthetic. Depending on the site of administration, its effects can last from 3 to 15 hours, making it ideal for managing post-operative pain through continuous peripheral nerve blocks.

Yes. Ropivacaine HCl is widely used in 2026 for Caudal Blocks and regional anesthesia in children due to its predictable clearance and reduced toxicity profile compared to older agents.

While the powder is used to create various strengths, clinical solutions in 2026 typically range from 0.2% (for chronic pain/labor) to 0.75% or 1.0% (for major surgical blocks).

Поставщик натурального порошка ропивакаина гидрохлорида hcl
Fournisseur de poudre naturelle de chlorhydrate de ropivacaïne hcl
Lieferant für natürliches Ropivacainhydrochlorid-hcl-Pulver
Proveedor de polvo natural de clorhidrato de ropivacaína hcl
Fornecedor de pó natural de cloridrato de ropivacaína hcl